Targeted therapy before surgery for HER2-altered lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (SHR-A1811 and Adebelimumab) given before surgery for people with a specific type of lung cancer that has changes in the HER2 gene. The goal is to see if this treatment can shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 18 to 75.
- Stage II, IIIA, or IIIB non-small cell lung cancer that can be surgically removed.
- Tumor has a change in the HER2 gene (tested on a biopsy).
- No prior cancer treatment for this lung cancer.
- Good overall health (able to walk and care for yourself) and no active autoimmune or serious heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial is testing a combination of two drugs (adebrelimab and trastuzumab rezetecan) for people with stage III lung cancer that has a HER2 alteration. The tumor must be unresectable (not removable by surgery). Participants must not have had prior systemic treatment for their lung cancer. They need to have measurable disease and be in generally good health.
This trial tests a combination of two drugs (SHR-A1921 and adebrelimab) for people with advanced non-small cell lung cancer whose cancer has grown after standard first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.